PANDAS/PANS in Children: Navigating the Controversies and Finding Evidence-Based Paths
"Demystifying Childhood Autoimmune Neuropsychiatric Disorders for Parents and Caregivers"
Since the late 1990s, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and its broader category, Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS), have become topics of significant discussion and, at times, heated debate. These conditions, characterized by a sudden onset of obsessive-compulsive behaviors, tics, and other neuropsychiatric symptoms in children, have left many parents and healthcare providers searching for answers.
The core of the controversy lies in several areas: the definitive role of streptococcal infections, the natural progression of these conditions, and the most effective treatments. Questions linger around the use of antibiotics, immunotherapies, and psychoactive medications, leaving families feeling uncertain and clinicians seeking clarity. This article aims to address these critical questions, offering a balanced view of current research, diagnostic criteria, and potential management strategies.
While firm proof supporting the autoimmune nature of PANDAS remains elusive, it’s crucial to tackle the questions surrounding diagnosis, treatment, and causes. This article aims to provide an overview of the working definitions of both PANDAS and PANS, assess existing research on interventions, and suggest a practical approach for addressing acute symptoms that align with these criteria. By providing a thorough summary, we want to help families feel supported, informed, and empowered to navigate the challenges of PANDAS/PANS.
Understanding PANDAS and PANS: What Are the Key Differences?
The concept of PANDAS initially emerged from the idea that its underlying mechanisms might be similar to those of Sydenham's chorea, a neurological disorder resulting from rheumatic fever. In 1998, the first diagnostic criteria for PANDAS were proposed, setting the stage for future research and clinical understanding.
- PANDAS: Specifically linked to streptococcal infections, primarily affecting prepubescent children. It focuses on tic disorders and obsessive-compulsive behaviors that appear suddenly following a strep infection.
- PANS: A broader category that includes cases with similar sudden-onset neuropsychiatric symptoms but not necessarily linked to streptococcal infections. PANS can occur at any age and includes a wider range of triggers beyond strep, such as other infections or environmental factors.
Limits in the Evidence
A systematic review of anti-inflammatory, antibacterial, and immunomodulatory treatments for children with PANS-like symptoms found substantial clinical and methodological diversity. Because there was no established diagnosis and all included studies had major risks of bias, including selection and detection bias, the reviewers did not pool results. A separate study estimating PANS/PANDAS incidence in three primary-care populations noted that some patients later diagnosed with these conditions were not counted because their initial evaluation was lacking or incomplete. Together, these findings highlight challenges in interpreting treatment evidence and identifying cases in clinical-population research.
Mixed Findings on Infection and Symptoms
A prospective longitudinal study reported an average of 0.42 newly acquired group A beta-hemolytic streptococcal (GABHS) infections per year among children with tic disorders and/or OCD, compared with 0.28 among controls. However, a systematic review and meta-analysis found no increased risk of GABHS infection in PANDAS cases versus controls (RR 0.99, 95% CI 0.56–1.73). It found a nonsignificant increase in symptom exacerbations temporally near GABHS infection (RR 2.33, 95% CI 0.63–8.70). Separately, whole-exome sequencing of 386 PANS patients and whole-genome sequencing of 10 severe cases identified candidate de novo or ultra-rare mutations in 21 patients across 11 genes, linked in the report to immune regulation, microglia, and neuronal synaptic function.
Final Thoughts: Empowering Families Through Understanding
The journey through understanding and managing PANDAS/PANS can be complex, but it doesn't have to be traveled alone. By staying informed, working closely with healthcare providers, and seeking support from advocacy groups and other families, parents can play a vital role in advocating for their children's needs. While research continues to evolve, a comprehensive approach that combines medical, therapeutic, and supportive care offers the best path forward for children and families affected by these challenging conditions.
Research Directions
A 2023 review describes its purpose as summarizing the current literature on PANDAS and PANS, conditions thought to be related to OCD, and presents the phenomenology of the PANDAS/PANS subtype of OCD and/or tic-related illness. The PANDAS Network’s research-priorities project frames PANDAS and PANS as forms of post-infectious basal ganglia encephalitis and focuses on improving diagnosis and treatment. Its research archive lists topics including folate receptor alpha autoantibodies in the PANS/PANDAS population and postacute sequelae of SARS-CoV-2 in children. These sources point to ongoing review and a range of topics for further study, rather than establishing definitive answers.
Guidance and Everyday Impacts
A 2025 American Academy of Pediatrics article says pediatric health care providers and clinicians need guidance to accurately diagnose and treat new-onset neuropsychiatric symptoms in children, including determining whether symptoms are compatible with PANS. A 2016 NCBI Bookshelf chapter describes its role as providing a history of PANDAS and information about its proposed association with Streptococcus pyogenes, tics, OCD, and Sydenham chorea. A PANDAS research-impact summary also highlights cognitive, graphomotor, and emotional challenges for children with PANDAS and the broader PANS diagnosis, including graphomotor impairments that can disrupt academic and social life. These sources address both clinical guidance needs and challenges affecting children beyond diagnosis alone.